Is the Price Right for Novo Nordisk?


Despite receiving approvals in the EU and Japan, Novo Nordisk's new insulin products Tresiba and Ryzodeg were given the red light by the FDA last week. Investors were shocked to hear the news, considering that an advisory committee that convened ahead of the official decision voted 8-4 in favor of approving the drug. Nevertheless, Novo Nordisk now has to complete a cardiovascular outcomes study in order to refile its NDAs for approval. In the meantime, Lantus, the long-acting insulin made by Sanofi , is set to continue its market dominance.

Reuters, however, recently reported that Novo Nordisk is planning on selling Tresiba at a higher price than Lantus in the U.K. In this video, health care analyst Max Macaluso discusses what this means for the company and how it can justify the higher price.

The future of MannKind?
Novo Nordisk and Sanofi are two established players in the diabetes space, but a small biotech company called MannKind is trying to revolutionize the way diabetes is treated around the world. But will the FDA put the kibosh on this product before it even hits the market? In a new premium research report on MannKind, these complex issues are made crystal clear, in addition to showing you why to buy or sell the stock today. To find out more -- and get a full year of free updates -- click here to grab your copy today.

The article Is the Price Right for Novo Nordisk? originally appeared on

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.